Official Title
Alglucosidase Alfa Temporary Access Program
Brief Summary

Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiencyof a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA isused by the body's cells to break down glycogen (a stored form of sugar) withinspecialized structures called lysosomes. In patients with Pompe disease, an excessiveamount of glycogen accumulates and is stored in various tissues, especially heart andskeletal muscle, which prevents their normal function. The objective of this expandedaccess study is to provide patients with Pompe disease in the United States (US), accessto alglucosidase alfa produced from a scaled up manufacturing process for a limited timeuntil production at this scale is approved for commercial use by the Food and DrugAdministration.

Approved for marketing
Glycogen Storage Disease Type II (GSD-II)
Pompe Disease (Late-Onset)
Acid Maltase Deficiency Disease
Glycogenosis 2

Biological: alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])

IV infusion: 20mg/kg qow
Other Name: Alglucosidase alfa

Eligibility Criteria

Inclusion Criteria:

- The patient or patient's legal guardian must provide signed, informed consent prior
to performing any study-related procedures.

- The patient must reside in the US.

- The patient must have a confirmed diagnosis of Pompe disease defined as documented
acid alpha-glucosidase (GAA) enzyme deficiency from any tissue source and/or GAA
gene mutations.

- The patient must have/had documented clinical signs and symptoms of Pompe disease.

- The patient must have/had prior treatment with alglucosidase alfa produced at
commercial scale OR be naive to enzyme replacement therapy (ERT) for the treatment
of Pompe disease and meet at least 1 of the following criteria: require a wheelchair
OR require some respiratory assistance for any number of hours (including night
time) through non-invasive ventilation.

- The patient must be capable of complying with the required program schedule of
assessments.

Exclusion Criteria:

- Females who are pregnant or lactating

- The patient has a clinical condition unrelated to Pompe disease that would interfere
with program assessments.

- The patient is currently enrolled in any clinical studies.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

Sheffield, Alabama, United States

Anchorage, Alaska, United States

Phoenix, Arizona, United States

Prescott, Arizona, United States

Scottsdale, Arizona, United States

Tucson, Arizona, United States

Bakersfield, California, United States

Beverly Hills, California, United States

Loma Linda, California, United States

Los Angeles, California, United States

Sacramento, California, United States

San Diego, California, United States

Stanford, California, United States

Aurora, Colorado, United States

Washington, District of Columbia, United States

Bradenton, Florida, United States

Coral Springs, Florida, United States

Daytona Beach, Florida, United States

Gainsville, Florida, United States

St. Petersburg, Florida, United States

Decatur, Georgia, United States

Boise, Idaho, United States

Chicago, Illinois, United States

Evansville, Indiana, United States

Iowa City, Iowa, United States

Kansas City, Kansas, United States

Louisville, Kentucky, United States

New Orleans, Louisiana, United States

Shreveport, Louisiana, United States

Augusta, Maine, United States

Baltimore, Maryland, United States

Boston, Massachusetts, United States

Springfield, Massachusetts, United States

Detroit, Michigan, United States

Grand Rapids, Michigan, United States

Lake Orion, Michigan, United States

Rochester Hills, Michigan, United States

St. Joseph, Michigan, United States

Minneapolis, Minnesota, United States

Missoula, Montana, United States

Omaha, Nebraska, United States

Midland Park, New Jersey, United States

Albuquerque, New Mexico, United States

Albany, New York, United States

Corning, New York, United States

Manhasset, New York, United States

New York, New York, United States

Asheville, North Carolina, United States

Durham, North Carolina, United States

Jacksonville, North Carolina, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States

Greenville, Ohio, United States

Toledo, Ohio, United States

Oklahoma City, Oklahoma, United States

Tulsa, Oklahoma, United States

Portland, Oregon, United States

Philadelphia, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Greenville, South Carolina, United States

West Colombia, South Carolina, United States

Houston, Texas, United States

San Antonio, Texas, United States

Waco, Texas, United States

Salt Lake City, Utah, United States

Charlottesville, Virginia, United States

Chesapeake, Virginia, United States

Newport News, Virginia, United States

Richmond, Virginia, United States

Winchester, Virginia, United States

Pullman, Washington, United States

Seattle, Washington, United States

Morgantown, West Virginia, United States

Green Bay, Wisconsin, United States

Medical Monitor, Study Director
Genzyme, a Sanofi Company

Genzyme, a Sanofi Company
NCT Number
Keywords
GSD-II, Pompe Disease, Glycogen Storage Disease II
MeSH Terms
Glycogen Storage Disease Type II
Glycogen Storage Disease
Deficiency Diseases